文献速递妇科肿瘤消化系统肿瘤

卡度尼利单抗(抗PD-1/CTLA-4双特异性抗体)治疗晚期实体瘤的安全性与抗肿瘤活性(COMPASSION-03):一项多中心、开放标签、1b/2期试验

Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
PubMed 文献 · Lancet Oncol · 2023-01-01

这项在中国30家医院开展的多中心、开放标签1b/2期试验纳入240例晚期实体瘤患者,评估卡度尼利单抗单药的安全性和抗肿瘤活性。剂量递增阶段未发生剂量限制性毒性,3-4级治疗相关不良事件发生率为28%。2期宫颈癌队列客观缓解率为32.3%,食管鳞癌为18.2%,肝细胞癌为16.7%。

要点

  • 剂量递增阶段未发生剂量限制性毒性。
  • 3-4级治疗相关不良事件发生于240例中的67例(28%)。
  • 宫颈癌队列客观缓解率32.3%(32/99,95%CI 23.3-42.5)。

核心结论

  • 卡度尼利单抗显示出令人鼓舞的肿瘤缓解率,安全性可控,提示其治疗晚期实体瘤的潜力。

研究设计与样本

  • 多中心、开放标签、1b/2期试验,在中国30家医院开展,2019年1月18日至2021年1月8日纳入240例患者(1b期83例,2期157例)。
  • 入组标准为18岁及以上、组织学或细胞学确诊的不可切除晚期实体瘤、至少一种既往系统治疗失败、ECOG体能状态评分0或1。
  • 排除既往接受过抗PD-1、抗PD-L1或抗CTLA-4治疗的患者。
  • 1b期剂量递增阶段给予卡度尼利单抗6 mg/kg和10 mg/kg静脉注射,每2周一次;剂量扩展阶段给予6 mg/kg和固定剂量450 mg静脉注射,每2周一次。
  • 2期在宫颈癌、食管鳞癌和肝细胞癌三个队列中给予卡度尼利单抗6 mg/kg静脉注射,每2周一次。

主要发现

  • 剂量递增阶段未发生剂量限制性毒性。
  • 3-4级治疗相关不良事件发生于240例中的67例(28%)。
  • 最常见的3级或以上治疗相关不良事件为贫血(7例[3%])、脂肪酶升高(4例[2%])、体重下降(3例[1%])、食欲下降(4例[2%])、中性粒细胞计数降低(3例[1%])和输液相关反应(2例[1%])。
  • 17例(7%)患者因治疗相关不良事件停止治疗;54例(23%)报告严重治疗相关不良事件,包括5例死亡(1例因心肌梗死,4例原因未知)。
  • 2期宫颈癌队列中位随访14.6个月(IQR 13.1-17.5),客观缓解率为32.3%(32/99,95%CI 23.3-42.5)。

关键数值与推荐

  • 主要终点:1b期安全性;2期基于RECIST 1.1的客观缓解率。
  • 安全性分析纳入所有接受至少一剂卡度尼利单抗的患者。
  • 抗肿瘤活性在宫颈癌队列的全分析集中评估,在食管鳞癌和肝细胞癌队列中于基线有可测量病灶且接受至少一剂卡度尼利单抗的所有患者中评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors targeting PD-1 or CTLA-4 individually have shown substantial clinical benefits in the treatment of malignancies. We aimed to assess the safety and antitumour activity of cadonilimab monotherapy, a bispecific PD-1/CTLA-4 antibody, in patients with advanced solid tumours. METHODS: This multicentre, open-label, phase 1b/2 trial was conducted across 30 hospitals in China. Patients aged 18 years or older with histologically or cytologically confirmed, unresectable advanced solid tumours, unsuccessful completion of at least one previous systemic therapy, and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion. Patients who had previously received anti-PD-1, anti-PD-L1, or anti-CTLA-4 treatment were not eligible for inclusion. In the dose escalation phase of phase 1b, patients received intravenous cadonilimab at 6 mg/kg and 10 mg/kg every 2 weeks. In the dose expansion phase of phase 1b, cadonilimab at 6 mg/kg and a fixed dose of 450 mg were given intravenously every 2 weeks. In phase 2, cadonilimab at 6 mg/kg was administered intravenously every 2 weeks in three cohorts: patients with cervical cancer, oesophageal squamous cell carcinoma, and hepatocellular carcinoma. The primary endpoints were the safety of cadonilimab in phase 1b and objective response rate in phase 2, based on the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. The safety analysis was done in all patients who received at least one dose of cadonilimab. Antitumour activity was assessed in the full analysis set for the cervical cancer cohort, and in all patients with measurable disease at baseline and who received at least one dose of cadonilimab in the oesophageal squamous cell carcinoma and hepatocellular carcinoma cohorts. The study is registered on ClinicalTrial.gov, NCT03852251, and closed to new participants; follow-up has been completed. FINDINGS: Between Jan 18, 2019, and Jan 8, 2021, 240 patients (83 [43 male and 40 female] in phase 1b and 157 in phase 2) were enrolled. Phase 2 enrolled 111 female patients with cervical cancer, 22 patients with oesophageal squamous cell carcinoma (15 male and seven female), and 24 patients with hepatocellular carcinoma (17 male and seven female). During dose escalation, no dose-limiting toxicities occurred. Grade 3-4 treatment-related adverse events occurred in 67 (28%) of 240 patients; the most frequent grade 3 or worse treatment-related adverse events were anaemia (seven [3%]), increased lipase (four [2%]), decreased bodyweight (three [1%]), decreased appetite (four [2%]), decreased neutrophil count (three [1%]), and infusion-related reaction (two [1%]). 17 (7%) patients discontinued treatment due to treatment-related adverse events. 54 (23%) of 240 patients reported serious treatment-related adverse events, including five patients who died (one due to myocardial infarction; cause unknown for four). In phase 2, in the cervical cancer cohort, with a median follow-up of 14·6 months (IQR 13·1-17·5), the objective response rate was 32·3% (32 of 99; 95% CI 23·3-42·5). In the oesophageal squamous cell carcinoma cohort, with a median follow-up of 17·9 months (IQR 4·0-15·1), the objective response rate was 18·2% (four of 22; 95% CI 5·2-40·3). In the hepatocellular carcinoma cohort, with a median follow-up of 19·6 months (IQR 8·7-19·8), the objective response rate was 16·7% (four of 24; 95% CI 4·7-37·4). INTERPRETATION: Cadonilimab showed an encouraging tumour response rate, with a manageable safety profile, suggesting the potential of cadonilimab for the treatment of advanced solid tumours. FUNDING: Akeso Biopharma. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Gao X, Xu N, Li Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial. Lancet Oncol. 2023. PMID: 37797632. doi:10.1016/S1470-2045(23)00411-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。